Clinical trial · no report yet · Phase 3
ADAURA 2
A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection
- NCT05120349 ↗
- Active, not recruiting
- AstraZeneca
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 14 | |
| Podcasts | 10 | |
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Double-blind, Randomised, Placebo-Controlled, International Study to Assess the Efficacy and Safety of Adjuvant Osimertinib Versus Placebo in Participants With EGFR Mutation-positive Stage IA2-IA3 Non-small Cell Lung Cancer, Following Complete Tumour Resection
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- Osimertinib; Placebo
- Arms
- Osimertinib · Experimental
- Placebo · Placebo comparator
- Enrollment
- 390
- Primary outcomes
- Disease-Free Survival (DFS) in high-risk stratum
- Sponsor
- AstraZeneca
- Start
- Feb 21, 2022
- Primary completion
- Aug 2, 2027 (estimated)
- Results posted
- No
- Registry record
- NCT05120349 · updated Jul 6, 2026
Publications
linked from the registry- Murat-Onana ML, Ramalingam SS, Janne PA, Gray JE, Ahn MJ, John T, Yatabe Y, Huang X, Rukazenkov Y, Javey M, Brown H, Li-Sucholeiki X. EGFR mutation testing across the osimertinib clinical program. Lung Cancer. 2025 Jun;204:108549. doi: 10.1016/j.lungcan.2025.108549. Epub 2025 Apr 18. PubMed 40311309